Back

Ranolazine therapy is associated with a reduced new diagnosis of diabetes mellitus in chronic coronary syndrome patients: the results of a real-world analysis of an Italian population

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in coronary artery disease: from bench to bedside (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Associate Professor Stefano Fumagalli

Internal and Specialist Medicine and Geriatric Arrhythmia Unit, Florence (Italy)

8 More presentations in this session

Presentation thumbnail
Platelet membrane coated r-SAK to improve thrombolytic efficacy by targeting thrombus
Miss R. Hua (Nanjing, CN)
Abstract Slides Video
Presentation thumbnail
AtheroVax: a peptide vaccine with a therapeutic effect in animal model of chronic inflammation
Professor E. Ramacciotti (Santo Andre, BR)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose cotransporter 2 inhibitor attenuates left ventricular dysfunction in post-myocardial infarction in rats via reducing cardiac mitochondrial impairment
Doctor C. Maneechote (Chiang Mai, TH)
Abstract Slides Video
Presentation thumbnail
A new free radical scavenger, resorcimoline, prevents ischaemia/reperfusion injury in the heart
Doctor K. Ueno (Oita, JP)
Abstract Slides Video
Presentation thumbnail
Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline glycaemic status and body mass index: a DAPA-MI substudy
Professor R. Storey (Sheffield, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in coronary artery disease: from bench to bedside (1)

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Ranolazine ameliorates palmitic acid-induced insulin resistance in HL-1 cardiomyocytes by Ca2+/ CaMKII modulation: an in vitro investigation and population-based cohort study
thumbnail
Congress Session
Optimising chronic coronary syndromes management: insights from bench to bedside
thumbnail
Congress Presentation
Real-life use of novel glucose lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART-registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources